- Latest available (Revised)
- Point in Time (28/10/2011)
- Original (As made)
Version Superseded: 14/08/2012
Point in time view as at 28/10/2011.
There are currently no known outstanding effects for the The Medicines for Human Use (Clinical Trials) Regulations 2004, PART 8.
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
47.—(1) Sections 107 to 116, 118, 119, 121 to 125, 127, 129, 131 and 132(1) of, and Schedule 3 to, the Act shall apply for the purposes of these Regulations, but with the modifications specified in Schedule 9.
(2) In those provisions as applying by virtue of paragraph (1), a reference to any part of those provisions or a part of any of them is a reference to the provision or part as so applying.
48.—(1) If an enforcement authority have objective grounds for considering that any person has contravened any provision to which this regulation applies, they may serve upon that person a notice in writing (in these Regulations referred to as an “infringement notice”)—
(a)informing him of the authority’s grounds for considering that the person has contravened one or more of those provisions;
(b)specifying the relevant provision of these Regulations;
(c)specifying the measures which the person must take in order to ensure that the contravention does not continue or, as the case may be, does not recur;
(d)requiring the person to take those measures, within such period as may be specified in the notice;
(e)warning the person that unless the requirements of sub-paragraph (d) are met, further action may be taken in respect of the contravention.
(2) An infringement notice may include directions as to the measures to be taken by the person on whom the notice is served to ensure that the contravention does not continue or, as the case may be, does not recur, including the different ways of securing compliance.
(3) If an enforcement authority serves an infringement notice in accordance with paragraph (1), they shall forthwith inform—
(a)the competent authorities of each EEA State, other than the United Kingdom;
(b)the relevant ethics committee; and
(c)the European Commission.
(4) This regulation applies to regulations [F13A, 12(1),] 22(b), 27, 28(1) to (3), 29, [F229A,] 30(2) [F3, 31A] and 32 to 35.
(5) In this regulation, “enforcement authority” means any Minister or body on whom a duty or power to enforce any provisions of these Regulations is imposed or conferred by or under sections 108 to 110 of the Act as applied by regulation 47.
Textual Amendments
F1Words in reg. 48(4) inserted (29.8.2006) by The Medicines for Human Use (Clinical Trials) Amendment Regulations 2006 (S.I. 2006/1928), regs. 1(1), 25(a)
F2Word in reg. 48(4) inserted (29.8.2006) by The Medicines for Human Use (Clinical Trials) Amendment Regulations 2006 (S.I. 2006/1928), regs. 1(1), 25(b)
F3Word in reg. 48(4) inserted (29.8.2006) by The Medicines for Human Use (Clinical Trials) Amendment Regulations 2006 (S.I. 2006/1928), regs. 1(1), 25(c)
49.—(1) Any person who contravenes any of the following provisions—
[F4(a)regulation 3A;]
[F5(aa)]regulation 12(1) and (2);
(b)regulation 13(1);
(c)regulation 27;
(d)regulation 28(1) to (3);
(e)regulation 29;
[F6(ee)regulation 29A;]
(f)regulation 30(2);
[F7(ff)regulation 31A(1) to (3) and (5) to (10);]
(g)regulation 32(1), (3), and (5) to (9)
(h)regulation 33(1) to (5)
(i)regulation 34
(j)regulation 35(1);
(k)regulation 36(1);
(l)regulation 42; and
(m)regulation 43(1) and (6),
shall be guilty of an offence.
(2) Any person who has in his possession a medicinal product for the purpose of selling or supplying it in contravention of regulation 13(1) shall be guilty of an offence.
(3) Any person who fails to comply with a notice of suspension or termination served on him under regulation 31, unless that notice has been withdrawn or revoked by the licensing authority, shall be guilty of an offence.
(4) Where an investigational medicinal product is manufactured, assembled or imported in contravention of regulation 36(1), any person who sells or supplies the product for the purposes of a clinical trial knowing or having reasonable cause to suspect that it was so manufactured, assembled or imported shall be guilty of offence.
(5) Where an investigational medicinal product is imported in contravention of regulation 36(1), any person who, otherwise than for the purpose of performing or exercising a duty or power imposed or conferred by or under these Regulations, the Act or any other enactment, is in possession of the product knowing or having reasonable cause to suspect that it was so imported shall be guilty of offence.
(6) Any sponsor who sells or supplies, or procures the sale or supply, of an investigational medicinal product—
(a)to a subject for the purposes of a clinical trial; or
(b)to a person for the purpose of administering the product to such a subject,
the labelling of which does not comply with regulation 46, shall be guilty of an offence.
(7) Any person who sells or supplies an investigational medicinal product—
(a)to a subject for the purposes of a clinical trial; or
(b)to a person for the purpose of administering the product to such a subject,
the labelling of which does not comply with regulation 46, knowing, or having reasonable cause to believe, that the labelling does not so comply, shall be guilty of an offence.
Textual Amendments
F4Reg. 49(1)(a) inserted (29.8.2006) by The Medicines for Human Use (Clinical Trials) Amendment Regulations 2006 (S.I. 2006/1928), regs. 1(1), 26(b)
F5Reg. 49(1)(a) renumbered as reg. 49(1)(aa) (29.8.2006) by The Medicines for Human Use (Clinical Trials) Amendment Regulations 2006 (S.I. 2006/1928), regs. 1(1), 26(a)
50.—(1) Any person who in the course of—
(a)making an application for an ethics committee opinion;
(b)making a request for authorisation to conduct a clinical trial; or
(c)making an application for the grant or variation of a manufacturing authorisation,
provides to the licensing authority or an ethics committee any relevant information which is false or misleading in a material particular shall be guilty of an offence.
(2) Any person who—
(a)is conducting a clinical trial authorised in accordance with these Regulations;
(b)is a sponsor of such a clinical trial;
(c)while acting under arrangements made with a sponsor of such a clinical trial, performs the functions of that sponsor; or
(d)holds a manufacturing authorisation,
and who, for the purposes of these Regulations, provides to the licensing authority or an ethics committee any relevant information which is false or misleading in a material particular shall be guilty of an offence.
(3) Any person who, for the purpose of being engaged as a qualified person in accordance with regulation 43, provides to the licensing authority or to the holder of a manufacturing authorisation any information which is false or misleading in a material particular shall be guilty of an offence.
(4) In this regulation, “relevant information” means any information which is relevant to an evaluation of—
(a)the safety, quality or efficacy of an investigational medicinal product;
(b)the safety or scientific validity of a clinical trial; or
(c)whether, with regard to a clinical trial, the conditions and principles of good clinical practice are being satisfied or adhered to.
51.—(1) A person does not commit an offence under these Regulations if he took all reasonable precautions and exercised all due diligence to avoid the commission of that offence.
(2) Where evidence is adduced which is sufficient to raise an issue with respect to that defence, the court or jury shall assume that the defence is satisfied unless the prosecution proves beyond reasonable doubt that it is not.
52. A person guilty of an offence under these Regulations shall be liable—
(a)on summary conviction to a fine not exceeding the statutory maximum or to imprisonment for a term not exceeding three months or to both;
(b)on conviction on indictment to a fine or to imprisonment for a term not exceeding two years or to both.
The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Whole Instrument you have selected contains over 200 provisions and might take some time to download.
Would you like to continue?
The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Schedules you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: